News

Genetics and Fertility: A Complex Relationship

Fertility is a crucial aspect of human biology influenced significantly by genetic factors. Researchers have identified specific genes that impact fertility by affecting hormone levels, the quality of gametes, and the reproductive anatomy. For instance, variations in the FMR1 gene are known to affect ovarian function, while other genes influence sperm mobility and quality. Understanding these genetic markers can help medical professionals better address and treat infertility issues.

Family Traits Passed Down Through Generations

Family traits, including physical characteristics, health predispositions, and even behavioral tendencies, are often passed down through generations via our DNA. Scientists have discovered that many attributes, such as eye color, height, and certain health risks, are directly linked to specific genetic sequences. More complex traits, like resilience to stress or predisposition to certain diseases, involve the interaction of multiple genes, influenced by environmental factors.

The Genetic Foundations of Longevity

Longevity, or the length of one’s life, is another aspect deeply entrenched in genetic material. Studies have shown that about 25% of the variation in human lifespan can be attributed to genetic factors. Genes related to cellular repair, metabolism, and immune function are particularly influential. For example, individuals with variations in the FOXO3 gene are often associated with increased lifespans, possibly due to enhanced cellular maintenance mechanisms.

Research Advances and Ethical Considerations

With the advent of technologies like CRISPR and other gene-editing tools, the possibility of altering genetic predispositions is becoming a reality. However, this raises significant ethical concerns, particularly regarding gene editing in embryos to enhance fertility or longevity traits. The debate centers around the potential for unintended consequences and the ethical implications of “designer babies.”

Implications for Healthcare and Society

The growing understanding of the genetic basis of fertility, family traits, and longevity has profound implications for healthcare. Genetic testing can now offer insights into a person’s likelihood of facing certain health challenges, potentially guiding personalized medical treatments and preventative measures. Additionally, these insights can help individuals and families make informed decisions about their health and reproductive planning.

Future Directions in Genetic Research

As genetic research progresses, scientists are increasingly hopeful about the potential to not only understand but also manipulate genetic factors to improve quality of life and health outcomes. Future research aims to further decode the genetic influences on fertility and longevity, potentially leading to breakthroughs in treatments for age-related diseases and infertility.

The exploration of the genetic basis of fertility, family characteristics, and longevity offers exciting prospects for the future of medicine and society. By continuing to delve into the genetic underpinnings of these crucial aspects of human life, researchers are paving the way for advancements that could transform how we understand and manage our biological inheritance. 

Reference Link – https://www.ox.ac.uk/news/2024-12-13-genetic-basis-fertility-family-and-longevity

to infections and diseases.  However, its less-discussed yet significant effect lies in how it disrupts fertility in both men and women. For individuals living with HIV who dream of becoming parents, infertility adds another layer of complexity. Thanks to advancements in reproductive technology, particularly in-vitro fertilization (IVF), the possibility of parenthood is now within reach.

IVF has emerged as a beacon of hope for HIV-positive individuals, offering a safe and effective pathway to conceive while minimizing the risk of transmission to their partners or children. Understanding how HIV affects fertility and how IVF can address these challenges sheds light on a transformative medical solution for affected couples.

How HIV Impacts Male Fertility

HIV can influence male fertility in several ways. The virus can compromise sperm quality by reducing sperm count, motility, and overall function. Chronic inflammation caused by HIV may damage the testes, where sperm production takes place, leading to poor sperm health. Additionally, HIV is often associated with lower testosterone levels, which can result in reduced libido and even impotence.

Men with HIV are also at an increased risk of secondary infections and systemic health issues, which can exacerbate fertility challenges. These factors combine to make natural conception difficult for many HIV-positive men.

How HIV Affects Female Fertility

For women, HIV significantly disrupts the reproductive system. Studies have shown that fertility rates among HIV-positive women are considerably lower compared to their HIV-negative counterparts. The virus can damage reproductive organs, including the ovaries and fallopian tubes, which are crucial for ovulation and fertilization.

Women with HIV often experience hormonal imbalances that interfere with regular menstrual cycles and ovulation. In addition, the risk of pelvic inflammatory disease (PID) is heightened, which can lead to scarring or blockage of the fallopian tubes, further complicating conception. Premature ovarian failure, a condition where the ovaries lose function earlier than expected, is also more common in women living with HIV, reducing both the quality and quantity of eggs.

How IVF Offers a Path to Parenthood

IVF is a groundbreaking solution for HIV-positive individuals facing fertility challenges. The process involves fertilizing an egg with sperm outside the body and implanting the resulting embryo into the uterus. For men with low sperm count or motility due to HIV, techniques like intracytoplasmic sperm injection (ICSI) can ensure fertilization by injecting a single sperm directly into the egg.

Another vital innovation is sperm washing, which separates sperm from the seminal fluid where the virus is concentrated. This significantly reduces the risk of HIV transmission to the partner or child during conception.

Women with HIV can also benefit greatly from IVF. For those with blocked fallopian tubes, ovulatory disorders, or other fertility issues, IVF bypasses these barriers, allowing fertilization to occur in a controlled environment. Advanced techniques like Preimplantation Genetic Testing (PGT) can be used to screen embryos for HIV and other genetic conditions, ensuring only healthy embryos are implanted.

Safe Options for High-Risk Cases

In cases where pregnancy poses a significant health risk to the mother, IVF combined with surrogacy offers an alternative route to parenthood. Using the couple’s egg and sperm, the embryo is transferred to a healthy surrogate, allowing the parents to have a biological child without endangering the mother’s health.

HIV-positive women can also maintain antiretroviral therapy (ART) during pregnancy, dramatically reducing the risk of transmitting the virus to the baby and ensuring a safer pregnancy journey.

A New Era of Hope

HIV no longer has to be a barrier to parenthood. With advancements in fertility treatments like IVF, individuals living with HIV can overcome infertility challenges and embrace the joys of family life. By combining medical innovation with compassionate care, the dream of becoming a parent is now a reality for many HIV-positive individuals.

Ref link – https://www.onlymyhealth.com/how-does-hiv-impact-fertility-and-how-can-ivf-help-12977821575  

narrowing the gap between their time-to-pregnancy and that of the general population.

RA, an autoimmune disease that causes chronic inflammation in the joints, is known to impair fertility in women. This can be particularly distressing for women trying to conceive, as the disease often disrupts hormonal balance and overall reproductive health. However, new data suggests that adopting a treat-to-target approach focused on disease remission can significantly reduce the time to conception.

What is the Treat-to-Target Approach?

The treat-to-target (T2T) strategy involves closely monitoring disease activity and adjusting treatment to achieve specific goals, such as disease remission or low disease activity. For women with RA looking to conceive, this approach emphasizes minimizing inflammation while ensuring medications are compatible with pregnancy.

Under the T2T paradigm, a combination of medications such as sulfasalazine, hydroxychloroquine, and TNF inhibitors, alongside low-dose prednisone when necessary, are used to manage RA symptoms.

New Findings on Fertility in Women with RA

The Preconception Counseling in Active RA (PreCARA) study provided valuable insights into how the T2T approach impacts fertility. Researchers analyzed data from 245 women in the PreCARA cohort and compared it with 215 women from an earlier study known as the Pregnancy-induced Amelioration of RA (PARA) cohort, which did not utilize the T2T strategy.

Key findings include:

• Time-to-Pregnancy Improvement: Women in the PreCARA cohort had a median time to pregnancy of 84 days—less than half the 196-day median observed in the PARA group.
• Lower Infertility Rates: Only 23% of PreCARA participants took longer than 12 months to conceive, compared to 42% in the PARA group.
• Better Disease Control: PreCARA participants had a lower average disease activity score (DAS28 CRP of 2.33) compared to the PARA group (DAS28 of 3.84).

The findings suggest that achieving and maintaining low disease activity before conception plays a crucial role in improving fertility outcomes.

Medication Use in Preconception Period

A critical aspect of the study was evaluating medication use during the preconception period:

• Fewer Steroids: Only 23% of PreCARA participants using prednisone exceeded a daily dose of 7.5 mg, compared to 48% in the PARA group.
• Increased Biologic Use: Over half (53%) of PreCARA patients used TNF inhibitors, compared to just 3% in the PARA cohort.

This shift in medication patterns, prioritizing biologics over higher steroid doses, aligns with the T2T strategy’s goal of minimizing systemic inflammation with fewer side effects.

Fertility Nearly Equal to General Population

“These findings are encouraging,” noted Dr. Radboud Dolhain, a lead researcher in the study. “With a treat-to-target approach, fertility outcomes in women with RA are nearly on par with those in the general population.”

For many women with RA, this represents a significant milestone. By achieving disease control and utilizing medications compatible with pregnancy, the T2T approach provides hope for women aspiring to start families while managing their condition.

The Path Forward

This study highlights the importance of personalized care in managing RA for women planning pregnancy. Rheumatologists are encouraged to adopt T2T strategies and collaborate with patients to optimize both disease control and reproductive health.

As research continues, the insights from the PreCARA study offer a compelling case for integrating treat-to-target approaches into standard RA care, especially for women navigating the dual challenges of managing their condition and building their families.

Reference – https://www.healio.com/news/rheumatology/20241126/treattotarget-approach-improves-fertility-in-women-with-rheumatoid-arthritis  

to assist men with severe infertility challenges, particularly those diagnosed with azoospermia—the absence of detectable sperm in semen. Dubbed the Sperm Tracking and Recovery (STAR) method, this innovative approach utilizes AI to locate and isolate sperm cells, significantly enhancing the chances of conception.

Developed by a dedicated team at Columbia University’s Fertility Center, the STAR method draws inspiration from techniques used by astrophysicists for exploring distant galaxies. “The same technologies employed in the search for extraterrestrial life are now being used to foster life on our planet,” stated Zev Williams, MD, PhD, Director of the Columbia University Fertility Center. This cutting-edge method promises to offer a lifeline to individuals who previously had little or no prospects of fathering a biological child.

Understanding the STAR Method

For men with azoospermia, finding viable sperm is akin to searching for a needle in a haystack. The STAR method simplifies this search through high-powered imaging that scans semen samples and captures over 8 million images in less than an hour. AI algorithms then analyze these images to identify and pinpoint sperm cells with remarkable speed and accuracy.

Once the sperm cells are detected, they are carefully isolated using a microfluidic chip. This chip channels the sperm into a specific area, minimizing the risk of damage. Subsequently, a specially designed robot extracts each sperm cell in milliseconds, a process that is far more gentle than traditional methods involving centrifugation or manual extraction, which can be painful and may compromise sperm viability.

The Impact of AI on Fertility Treatments

The introduction of the STAR method represents a significant advancement over previous techniques, which were not only invasive and costly but also less effective for men with extremely low sperm counts. “Our approach eliminates the need for invasive surgical procedures and reduces the potential for inflammation and hormonal disruptions,” explained Dr. Williams.

This technology not only maintains the structural integrity of the sperm but also preserves its functional viability, providing a more conducive environment for fertilization. Once extracted, the sperm can be used immediately for in vitro fertilization (IVF) procedures or frozen for future attempts.

A New Era in Reproductive Health

The implications of the STAR method extend beyond just technical innovation; they signify a potential shift in how fertility issues are approached and treated. For many men, this could mean a transition from uncertainty and despair to hope and possibility. “Many of my patients who were once told they could never father children are now seeing a new horizon,” Williams noted optimistically.

As Columbia Fertility continues to refine and enhance this technology, the potential for its application in other areas of reproductive health remains vast. The STAR method is not just a scientific achievement; it is a beacon of hope for countless individuals dreaming of parenthood.

Ref link – https://www.thebump.com/news/ai-to-identify-sperm

that could revolutionize the success rates of In Vitro Fertilization (IVF). This innovative technology aims to make embryo selection faster, safer, and more cost-effective, potentially easing the emotional and financial burdens faced by couples undergoing fertility treatments.

The Science Behind the Microchip

The new microchip, unveiled in research published in the Human Reproduction journal, leverages light-emitting technology to measure the energy output of embryos. This metric is crucial for determining embryo health, making it a key factor in selecting the most viable candidates for implantation. The collaboration between reproductive science experts at the University of New South Wales (UNSW) and engineers at Monash University has focused on integrating advanced imaging capabilities into the microchip, initially tested on live mouse embryos.

Expert Insights

Dr. Fabrizzio Horta, a senior lecturer at UNSW and a pivotal figure in the research team, emphasized the potential impact of this technology. “By harnessing sophisticated and advanced technology on this microchip, we can enhance our understanding of embryo viability at a significantly reduced cost,” stated Dr. Horta, whose previous affiliation with Monash University played a crucial role in the project’s inception.

A Closer Look at the Technology

The novel device, about the size of the kangaroo head on an Australian $1 coin, uses microlenses to illuminate individual embryos, measuring their energy output without inflicting damage. This non-invasive method contrasts sharply with the current practices involving embryo biopsies for genetic testing, which are not only costly and time-consuming but also pose risks to the embryos.

Current Practices and Innovations

Embryo selection in IVF clinics currently depends heavily on the subjective assessment of specialists using standard optical microscopes. The reliance on operator expertise and expensive genetic testing often extends the IVF process, compounding the emotional and financial strain on couples.

The Future of IVF

Dr. Horta highlighted the efficiency of the new device, saying, “The device enables us to reconstruct high-resolution images of an embryo’s metabolic activity, which are indicative of genetic or metabolic abnormalities.” He pointed out that the closest existing technologies are complex research systems costing around $1 million and unsuitable for clinical use. In contrast, the microchip could be produced at a fraction of the cost, paving the way for its integration into clinical IVF workflows and potentially benefiting research and animal industries.

Moving Forward

The technology has already been submitted for patent filing by Monash University, reflecting its innovative design and scalability. The research team is currently exploring investment opportunities and the possibility of launching a spinout company to commercialize the microchip globally, aiming to make IVF a less daunting challenge for millions of couples worldwide.

This structured approach with subheadings makes the article more engaging and easier to follow, enhancing the overall reading experience.

Reference article – https://www.unsw.edu.au/news/2024/11/the-new-microchip-that-could-boost-ivf-success-rates

Plasma (PRP) therapy, offers new hope. This innovative approach is showing promising results in ovarian rejuvenation, potentially turning the tide for women struggling with infertility issues.

The Science of Ovarian PRP: 

Ovarian PRP therapy utilizes the patient’s own blood platelets, which are known for their healing properties and growth factors. The process begins with extracting a small amount of the patient’s blood, which is then processed in a centrifuge to concentrate the platelets. This platelet-rich plasma is then injected directly into the ovaries, aiming to stimulate ovarian function by promoting tissue repair and new cell growth.

Dr. Seema Patel, a renowned fertility specialist in Mumbai, explains, “The growth factors released by PRP can enhance the ovarian microenvironment, potentially increasing egg quality and quantity. This can be particularly beneficial for women who are older or have poor ovarian reserve.”

Clinical Evidence and Outcomes: 

Recent studies have shown encouraging results, with many patients experiencing improved ovarian response and a significant increase in pregnancy rates following PRP treatment. A landmark study published in the Journal of Reproductive Medicine in 2023 reported that 60% of participants who underwent ovarian PRP saw an improvement in their egg retrieval outcomes during subsequent IVF cycles.

“While the data is still emerging, the anecdotal successes provide substantial hope for the future of infertility treatments,” says Dr. Patel.

Patient Perspectives: 

Many women have turned to ovarian PRP as a last resort after other fertility treatments have failed. One such patient, Priya Kumari, shared her journey: “After years of unsuccessful IVF attempts, I tried ovarian PRP as a final attempt before considering egg donation. To my surprise, I conceived naturally within three months of the treatment.”

Challenges and Considerations: 

Despite its potential, ovarian PRP therapy is not a universal solution. The effectiveness can vary based on individual factors such as age, underlying health conditions, and the extent of ovarian ageing. Moreover, the treatment is still under clinical evaluation, and long-term outcomes are yet to be fully understood.

Future Directions: 

The field of reproductive medicine is rapidly evolving, and ovarian PRP is at the forefront of this innovation. Ongoing research aims to refine the treatment protocols and identify which patient populations will benefit the most. As Dr. Patel notes, “The ultimate goal is to make infertility a less daunting challenge, giving more women the chance to fulfil their dreams of motherhood.”

Our Takeaway: 

Ovarian PRP therapy emerges as a promising frontier in the quest to tackle infertility, presenting a glimmer of hope for many who have faced considerable challenges in conceiving. However, it’s important to approach this technology with a balanced perspective. While the treatment has heralded significant improvements for many patients, it is not foolproof. The effectiveness of ovarian PRP can vary significantly depending on individual factors such as age, overall health, and specific fertility issues. 

Medical professionals advise caution, emphasizing that while PRP therapy can be a part of the solution, it is not a guaranteed cure for all types of infertility. As the scientific community continues to research and understand the full scope and limitations of this treatment, it is crucial for patients to have comprehensive consultations with their healthcare providers to understand the best approach to their unique situations. This cautious optimism underscores the importance of ongoing research and tailored medical advice in the evolving landscape of reproductive health treatments.

Reference – https://www.hindustantimes.com/lifestyle/health/ageing-ovaries-this-new-therapy-might-be-the-fertility-solution-youve-been-waiting-for-101732951290313.html 

of BELA, an AI-based system developed by researchers at Weill Cornell Medicine. This cutting-edge system is revolutionizing the way embryos are assessed during In Vitro Fertilization (IVF) processes, offering an unprecedented level of accuracy and objectivity.

The Genesis and Capabilities of BELA 

BELA, which stands for the Bioengineered Embryo Learning Assessment, utilizes machine learning algorithms to analyze time-lapse video images of embryos along with maternal age data to assess their chromosomal status. This marks a significant departure from traditional methods which often require subjective analysis by embryologists and sometimes invasive biopsy-like procedures for preimplantation genetic testing for aneuploidy (PGT-A).

Dr. Iman Hajirasouliha, the project’s senior author, highlights that BELA’s use of extensive image data allows it to generate predictions with greater reliability. “Our system is designed to automate and refine how we evaluate embryos, making the process less dependent on human interpretation and more grounded in quantitative data,” explains Dr. Hajirasouliha.

Testing and Validation 

The effectiveness of BELA was rigorously tested across several datasets, including those from large IVF clinics in Florida and Spain, in addition to Weill Cornell Medicine’s own database. The system not only showed improved accuracy in identifying euploid (normal) and aneuploid (abnormal) embryos but also demonstrated consistency across different environments, underscoring its potential for widespread clinical use.

Implications for Future IVF Treatments 

The implications of integrating BELA into clinical practice are profound. By providing a more accurate assessment of embryo viability, BELA can potentially increase the success rates of IVF treatments, reducing both the emotional toll on prospective parents and the often prohibitive costs associated with multiple IVF cycles.

Expanding Access and Advancing Care 

Looking forward, the researchers are planning a randomized, controlled clinical trial to further validate BELA’s utility in live clinical settings. Dr. Nikica Zaninovic, who oversees the embryology work at Weill Cornell, believes that systems like BELA could democratize access to advanced IVF technology. “By enhancing the precision and efficiency of embryo selection, we can extend high-quality reproductive care to regions and communities that previously had limited access,” he states.

Beyond Ploidy Assessment 

Moreover, the research team envisions broader applications for BELA. Suraj Rajendran, the study’s first author, suggests that the AI system could also be adapted for other crucial aspects of embryology, such as predicting developmental stages and overall embryo quality. “BELA is just the beginning. We’re exploring how this technology can support various facets of embryology, potentially transforming the field,” Rajendran adds.

As 2024 progresses, the promise of AI in enhancing IVF treatments continues to unfold, with BELA at the forefront of this technological revolution. This breakthrough not only signifies a leap forward in fertility medicine but also reflects the broader potential of AI to reshape healthcare practices for the betterment of patient outcomes worldwide.

  faced by HIV-positive women, particularly concerning their reproductive health and the safe prevention of HIV transmission to unborn children. This year’s observance brings promising advancements in technology, legislative reforms, and innovative healthcare strategies designed to improve outcomes for women grappling with HIV.

Technological Advancements in Treating HIV-Positive Women

Recent years have seen remarkable technological progress in monitoring and managing the health of HIV-positive women. Telemedicine platforms have expanded access to specialist consultations, allowing for continuous monitoring of women’s health status from afar. Additionally, digital health tools, such as apps that track medication adherence and viral load fluctuations, play a crucial role in personalizing patient care.

In the realm of reproductive health, new diagnostic tools have been developed that provide quicker and more accurate assessments of hormonal levels and immune system status. These technologies are crucial for promptly addressing the fertility issues often associated with HIV, such as menstrual irregularities and early onset menopause.

Legislative and Policy Shifts

On the legislative front, several countries have introduced laws that enhance the rights and healthcare access for HIV-positive women, especially in terms of reproductive health. These laws aim to eliminate discrimination in healthcare settings, ensuring that HIV-positive women receive the same quality of reproductive health services as their HIV-negative counterparts.

Moreover, global health policies have been revised to include funding for advanced reproductive technologies (ART) for HIV-positive women. This includes support for procedures such as sperm washing, which significantly reduces the risk of HIV transmission between partners during conception attempts, and in vitro fertilization (IVF), ensuring safer pregnancy planning and execution.

Preventing HIV Transmission to Unborn Children

One of the most critical areas of focus is the prevention of mother-to-child transmission of HIV. Recent advances in antiretroviral therapy (ART) have been highly effective in reducing viral loads in pregnant women to undetectable levels, which dramatically decreases the risk of transmission to the infant.

Additionally, ongoing research has led to the development of microbicidal vaginal gels that women can apply before intercourse or at the onset of labor to reduce viral transmission risks. These gels are a breakthrough for women who do not consistently have access to ART or who discover their HIV status late in pregnancy.

Looking Ahead

Healthcare systems worldwide are encouraged to integrate these advancements and policy shifts into their practice. By adopting a more holistic approach that includes cutting-edge technology, supportive legislation, and comprehensive healthcare, the medical community can significantly improve fertility management and overall health outcomes for HIV-positive women.

This World AIDS Day, the call to action is clear: embrace innovation, advocate for equitable policies, and ensure that every HIV-positive woman receives the care and support she needs to manage her health and safely plan her family.